Rosenzweig-Lipson S[au] - Search Results

Year	Number of Results
1992	2
1993	2
1994	2
1995	3
1996	1
1997	2
2000	4
2002	1
2004	1
2005	5
2006	6
2007	10
2008	15
2009	10
2010	7
2011	5
2012	5
2013	3
2014	1
2017	1
2018	1
2022	0

1

5-HT(2C) agonists as therapeutics for the treatment of schizophrenia.

Rosenzweig-Lipson S, Comery TA, Marquis KL, Gross J, Dunlop J. Rosenzweig-Lipson S, et al. Handb Exp Pharmacol. 2012;(213):147-65. doi: 10.1007/978-3-642-25758-2_6. Handb Exp Pharmacol. 2012. PMID: 23027415 Review.

2

Differentiating antidepressants of the future: efficacy and safety.

Rosenzweig-Lipson S, Beyer CE, Hughes ZA, Khawaja X, Rajarao SJ, Malberg JE, Rahman Z, Ring RH, Schechter LE. Rosenzweig-Lipson S, et al. Pharmacol Ther. 2007 Jan;113(1):134-53. doi: 10.1016/j.pharmthera.2006.07.002. Epub 2006 Sep 27. Pharmacol Ther. 2007. PMID: 17010443 Review.

3

5-HT2C receptor agonists as an innovative approach for psychiatric disorders.

Rosenzweig-Lipson S, Dunlop J, Marquis KL. Rosenzweig-Lipson S, et al. Drug News Perspect. 2007 Nov;20(9):565-71. doi: 10.1358/dnp.2007.20.9.1162244. Drug News Perspect. 2007. PMID: 18176661 Review.

4

Pharmacological profile of the 5-HT(2C) receptor agonist WAY-163909; therapeutic potential in multiple indications.

Dunlop J, Marquis KL, Lim HK, Leung L, Kao J, Cheesman C, Rosenzweig-Lipson S. Dunlop J, et al. Among authors: rosenzweig lipson s. CNS Drug Rev. 2006 Fall-Winter;12(3-4):167-77. doi: 10.1111/j.1527-3458.2006.00167.x. CNS Drug Rev. 2006. PMID: 17227285 Free PMC article. Review.

5

Innovative approaches for the development of antidepressant drugs: current and future strategies.

Schechter LE, Ring RH, Beyer CE, Hughes ZA, Khawaja X, Malberg JE, Rosenzweig-Lipson S. Schechter LE, et al. Among authors: rosenzweig lipson s. NeuroRx. 2005 Oct;2(4):590-611. doi: 10.1602/neurorx.2.4.590. NeuroRx. 2005. PMID: 16489368 Free PMC article. Review.

6

Treatment with levetiracetam improves cognition in a ketamine rat model of schizophrenia.

Koh MT, Shao Y, Rosenzweig-Lipson S, Gallagher M. Koh MT, et al. Among authors: rosenzweig lipson s. Schizophr Res. 2018 Mar;193:119-125. doi: 10.1016/j.schres.2017.06.027. Epub 2017 Jun 17. Schizophr Res. 2018. PMID: 28634087 Free PMC article.

7

Novel 1-aminoethyl-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines are potent 5-HT(6) agonists.

Bernotas RC, Lenicek S, Antane S, Cole DC, Harrison BL, Robichaud AJ, Zhang GM, Smith D, Platt B, Lin Q, Li P, Coupet J, Rosenzweig-Lipson S, Beyer CE, Schechter LE. Bernotas RC, et al. Among authors: rosenzweig lipson s. Bioorg Med Chem. 2009 Jul 15;17(14):5153-63. doi: 10.1016/j.bmc.2009.05.055. Epub 2009 May 29. Bioorg Med Chem. 2009. PMID: 19523834

8

Alpha 2A-adrenoceptors enhance the serotonergic effects of fluoxetine.

Beyer CE, Lin Q, Rosenzweig-Lipson S, Schechter LE. Beyer CE, et al. Among authors: rosenzweig lipson s. Eur J Pharmacol. 2006 Jun 13;539(3):164-7. doi: 10.1016/j.ejphar.2006.03.083. Epub 2006 Apr 19. Eur J Pharmacol. 2006. PMID: 16714015

9

Schedule-induced polydipsia: a rat model of obsessive-compulsive disorder.

Platt B, Beyer CE, Schechter LE, Rosenzweig-Lipson S. Platt B, et al. Among authors: rosenzweig lipson s. Curr Protoc Neurosci. 2008 Apr;Chapter 9:Unit 9.27. doi: 10.1002/0471142301.ns0927s43. Curr Protoc Neurosci. 2008. PMID: 18428677

10

A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia.

Shen JH, Zhao Y, Rosenzweig-Lipson S, Popp D, Williams JB, Giller E, Detke MJ, Kane JM. Shen JH, et al. Among authors: rosenzweig lipson s. J Psychiatr Res. 2014 Jun;53:14-22. doi: 10.1016/j.jpsychires.2014.02.012. Epub 2014 Feb 24. J Psychiatr Res. 2014. PMID: 24613032 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results